Oncología médica
Especialidad
Hospital Universitario de Salamanca
Salamanca, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Salamanca (35)
2024
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789
2023
-
Immunogenicity of COVID-19 vaccines in lung cancer patients
Lung Cancer, Vol. 184
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2022
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
-
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
Translational Lung Cancer Research, Vol. 11, Núm. 1, pp. 53-63
-
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Journal for immunotherapy of cancer, Vol. 10, Núm. 9
2021
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8
-
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Nature Communications, Vol. 12, Núm. 1
-
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
-
The economic burden of metastatic breast cancer in Spain
European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
-
First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536
-
Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: Results of the observational “LORENA” study
OncoTargets and Therapy, Vol. 11, pp. 5845-5852
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556